Q1 2027 IPCA Laboratories Ltd Earnings Call Transcript
Key Points
- Ipca Laboratories Ltd (BOM:524494) reported strong consolidated revenue growth of 21% year-over-year, reaching INR 2,788 crore in Q1 FY27.
- Consolidated EBITDA margin improved significantly to 22.88% from 18.39% in the prior year, driven by operational efficiencies and scale.
- The domestic formulation business grew 13%, outperforming the IPM in both chronic (17.2% growth) and acute (8.9% growth) segments.
- Export business surged 34%, with the European market delivering exceptional growth of ~70%, and the institutional generic business more than doubling.
- The company revised its FY27 revenue growth guidance upward to 14-16% and EBITDA margin guidance to ~23%, reflecting confidence in continued strong performance.
- Ipca Laboratories Ltd (BOM:524494) has a strong balance sheet with minimal debt (INR 193 crore) and zero working capital debt, reducing interest costs and financial risk.
- The biosimilar pipeline is advancing well, with seven candidates in development and two in engineering batches, targeting global markets with high-value products.
- The company faces significant headwinds from rising raw material prices, container shortages, and a threefold increase in freight costs, particularly to South America and the US.
- The anti-malarial segment declined by 24% in Q1 FY27, although it now constitutes only ~1% of overall business.
- The institutional generic business growth was inflated by ~INR 40 crore of shipments delayed from March to April, masking a more modest underlying trend.
- The US business growth is expected to moderate to 15-17% annually, with only 3-4 new product launches per year from Ipca and Unicam combined.
- Unicam's margin improvement is partly dependent on rupee depreciation, and its own portfolio growth was only 9%, with no immediate benefit from Ipca's API supply.
- The company is incurring significant capex (INR 700-800 crore) for capacity expansion and biosimilar development, which may pressure near-term cash flows.
- Logistics costs are expected to rise further in July-August, potentially impacting margins in the coming quarters despite current improvements.
Hi, good afternoon, everyone, and a very warm welcome to Collapse 2,127 Earnings Call, hosted by Dan Caplan Advisors Limited. On the call today, we have representing Collapse Management, Mr. A.K. Jain, Managing Director, and Mr. Harish Kamath, Corporate Counsel and Company Directory. I will handle the call for Mr. Jain to make opening comments, and then we'll open the floor for questions. Please go ahead, sir.
Thank you, Nathan, and Dan Caplan for organizing this call.
Today's hearing call and discussion and answer given may include some forward-looking statement based on our current business expectation.
This must be viewed in conjunction with risk that pharmaceutical business faces.
Our actual future financial performance may differ from what is projected and perceived. You might use your own judgment on information given during the call.
Our domestic formulation business for Q1 FY27 has delivered
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
